KIORA PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
KIORA PHARMACEUTICALS, INC. (KPRX) had Debt Securities, Available-for-sale, Amortized Cost of $9.77 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-07
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $9.77M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $2.92M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $8.38M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $13.85M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $9.77M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $2.92M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $8.38M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $13.85M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $19.64M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $20.32M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $22.97M 10-K · filed 2026-03-25 |
| 2024-09-30 | $23.32M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $21.25M 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |